Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).

J&J's Stelara Gets Approval in EU for Ulcerative Colitis

PepsiCo

Coke's dividend is sweet, but these two stocks offer comparable yields and better long-term prospects.

Forget Coca-Cola: Here Are 2 Better Dividend Stocks

Disney

NextEra Energy

These income stocks are phased by virtually nothing, making them incredibly safe bets to deliver over the long run.

3 Surefire Dividend Stocks to Pass On to Your Kids or Grandkids

There's a good chance that Johnson & Johnson will be overwhelmed by two huge legal battles, causing JNJ stock to drop tremendously. 
The post It’s Time to Short Johnson & Johnson Stock appeared first on InvestorPlace.

It’s Time to Short Johnson & Johnson Stock

Tesla

Investors should wait out these three big names. There may be better entry points later in the year.

3 Large-Cap Stocks to Sell in September

Allergan

Endo International

Mallinckrodt PLC

Teva Pharmaceutical

Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.

Will Opioid Litigation Take its Toll on Pharma Companies?

Dow component Johnson & Johnson is trading dangerously close to 2018 support after yet another legal setback.

Time Is Running Out for Johnson & Johnson Bulls

Johnson & Johnson and others profited from addiction and death – and yet they still don’t think they’ve done anything wrong

Drug makers conspired to worsen the opioid crisis. They have blood on their hands | Chris McGreal

An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.

J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?

Moody's revised its outlook on J&J's top-tier credit rating to "negative" from "stable" reflecting the company's financial exposure to opioid-related litigation.

J&J is at risk of losing its AAA credit rating following Oklahoma opioid verdict

The market bounces back while Erique and Danny talk about Whiskey, Johnson and Johnson and continued trade war. The portfolios stay put while showing a lot of green, see what happens on this episode of Paper Traders.

Johnson and Johnson Opioid Lawsuit and More Doom and Gloom

How much Johnson & Johnson will actually benefit is unclear.

Trump Wants the VA to Get as Much of This Drug as It Can

Chipotle

Costco

Starbucks

Shopify

Chipotle, Starbucks, J&J, Shopify and Costco are our top stock trades. Here's how to trade them.

5 Top Stock Trades for Wednesday: CMG, SBUX, JNJ, SHOP & COST

Oklahoma's unusual use of nuisance law to win it's landmark suit against Johnson & Johnson could spur other states to amend their opioid cases to include the statute.

Oklahoma uses century-old property law to win J&J opioid suit — other states could follow

Johnson & Johnson’s (NYSE:JNJ) litigation expenses are on the rise with several lawsuits for different products, including talc, hip-plant, and blood thinner among others, piling up. As a result, the company’s total expenses are rising, though the contribution of litigation expenses to total expe.

Here's How Rising Litigation Charges Are Impacting Johnson & Johnson's Earnings

The Cleveland County District Court in Oklahoma ordered Johnson & Johnson (NYSE: JNJ) and its Janssen unit to pay $572 million to settle a lawsuit relating to their opioid drugs.

Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive

The J&J opioid ruling 2019 for the case in Oklahoma has been decided and it will have the company paying a fine to the state.

J&J Opioid Ruling 2019: 13 Things to Know

When companies run into legal issues in which they face potentially endless numbers of trials in numerous venues in America, it can create a tough time managing them.

Opioid Verdict: A Possible Victory for Johnson & Johnson and Loss for Everyone Else?

A court ordered J&J (JNJ) to pay $527 million in the Oklahoma litigation related to abuse of its opioid-based drugs. The company is facing similar litigation in multiple states.

J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case

Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.

J&J to Pay $572M in Opioid Case

Shares of pharmaceutical companies surged in after-hours trading following a smaller-than-expected fine for Johnson & Johnson.

Shares of pharma companies soar after Johnson & Johnson opioid fine

Johnson & Johnson will be forced to pay more than a half-billion dollars in damages after an Oklahoma judge on Monday ruled the drug maker accountable for fueling the state’s opioid epidemic, according to a report. The pharmaceutical giant will be forced to pay the state of Oklahoma $572 million as part of the landmark.

Johnson & Johnson to pay $500M in damages over opioid crisis

Drugmaker Johnson & Johnson must pay $572m (£469m) for helping fuel the  opioid crisis in a US state, a judge has ruled.

Drugmaker ordered to pay $572m for 'helping fuel opioid crisis'

Shares of Johnson & Johnson rose 4% in after-hours trade Monday after a judge ordered the consumer-products giant to pay $572 million for contributing to the opioid crisis in Oklahoma.

J&J stock up 4% after judge fines company less than some expected in landmark opioid case

Johnson & Johnson (NYSE: JNJ) and its prescription drugs unit are responsible for helping fuel Oklahoma's opioid drug problem, a judge ruled Monday, making the conglomerate the first to be held to blame by a court for the epidemic.

News for Johnson & Johnson Stock (JNJ)